IPCALAB vs NGLFINE: Stock Comparison

IPCA Laboratories Limited vs NGL Fine-Chem Limited

Live data: 22 July 2026, 3:02 PM IST • Source: NSE and company filings

IPCA Laboratories Limited is the larger company by market capitalisation. IPCA Laboratories Limited shows a lower P/E, a higher ROE and a higher dividend yield, while NGL Fine-Chem Limited shows faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of IPCA Laboratories Limited and NGL Fine-Chem Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, IPCALAB is more favourable on 8 of 13 scored metrics and NGLFINE on 5These counts are context-free and are not an overall rating.

Key Differences

Market Cap
IPCALAB is the larger company
₹45,033 Cr vs ₹2,008 Cr
P/E Ratio
IPCALAB has a lower P/E
39.94x vs 41.23x
P/B Ratio
IPCALAB has a lower P/B
5.65x vs 6.03x
EPS
NGLFINE has higher earnings per share
₹78.04 vs ₹45.05
Dividend Yield
IPCALAB has a higher dividend yield
0.33% vs 0.05%
Revenue Growth (TTM YoY)
NGLFINE has faster revenue growth
57.2% vs 6.2%
EPS Growth (TTM YoY)
NGLFINE has faster EPS growth
1,539.8% vs 341.6%
Qtr Sales Growth
NGLFINE has stronger quarterly sales growth
57.1% vs 6.31%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricIPCALABNGLFINE
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricIPCALABNGLFINE
Live Price₹1,788.5₹3,262.2
Day Change-0.58%0.77%
Volume1.74 L5,421
52-Week High₹1,944.9₹3,329
52-Week Low₹1,251.6₹1,175.5
Distance from 52W High-8.04%-2.01%

Valuation

MetricIPCALABNGLFINE
Market Cap₹45,033 Cr₹2,008 Cr
P/E Ratio39.94x41.23x
P/B Ratio5.65x6.03x
EPS₹45.05₹78.04
Book Value₹317.84₹532.95
Dividend Yield0.33%0.05%

Growth

MetricIPCALABNGLFINE
Revenue Growth (TTM YoY)6.2%57.2%
EPS Growth (TTM YoY)341.6%1,539.8%
Qtr Sales Growth6.31%57.1%
Qtr Profit Growth80.9%2,398%

Profitability & Leverage

MetricIPCALABNGLFINE
ROE16%15.7%
ROCE17.3%17%
Net Margin11.83%9.59%
Operating Margin20.5%14.5%
Debt to Equity0.1x0.33x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricIPCALABNGLFINE
Promoter Holding44.72%72.74%
FII Holding10.73% 0.1 pp0.03% 0.03 pp
DII Holding37.37% 0.08 pp0%
Public Holding7.18% 0.02 pp27.24% 0.02 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: IPCA Laboratories Limited and NGL Fine-Chem Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.